LRP1B mutation has been associated with increased immune cell infiltration and elevated expression of immune-related genes in NSCLC patients with adenocarcinoma treated with ICB, suggesting a possible role in the improved response to ICB [72, 73]. This evidence concerns the gene LRP1B and adenocarcinoma.